Upstream Bio (UPB) Liabilities and Shareholders Equity (2023 - 2026)

Upstream Bio's Liabilities and Shareholders Equity history runs 4 years deep, the most recent figure standing at $318.1 million for Q1 2026.

• On a quarterly basis, Liabilities and Shareholders Equity fell 30.28% year-over-year to $318.1 million in Q1 2026; TTM through Mar 2026 was $1.5 billion, a 26.73% increase from a year earlier, with the FY2025 full-year figure at $353.8 million, down 26.56% from the prior year.
• Liabilities and Shareholders Equity slipped to $318.1 million in Q1 2026 per UPB's latest filing, from $353.8 million in the prior quarter.
• Across five years, Liabilities and Shareholders Equity topped out at $481.7 million in Q4 2024 and bottomed at $117.2 million in Q4 2023.
• The 4-year median for Liabilities and Shareholders Equity is $372.5 million (2025), against an average of $346.4 million.
• Across the five-year window, Liabilities and Shareholders Equity soared 311.03% in 2024 and sank 30.28% in 2026, its largest moves.
• Year by year, Liabilities and Shareholders Equity stood at $117.2 million in 2023, then jumped by 311.03% to $481.7 million in 2024, then decreased by 26.56% to $353.8 million in 2025, then declined by 10.1% to $318.1 million in 2026.
• Per Business Quant, the three latest UPB Liabilities and Shareholders Equity figures stand at $318.1 million (Q1 2026), $353.8 million (Q4 2025), and $391.2 million (Q3 2025).